Evelyn Singleton

Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®)

Christopher L. Bacon, Evelyn Singleton, Bethany L. Brady et al. · Haemophilia · 2011 · 34 citations

Immunology, Pathology, Pharmacotherapy +16

Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII

Jude Smith, Mary Kavanagh, Beatrice Nolan et al. · Thrombosis and Haemostasis · 2007 · 20 citations

Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study

Megan Kennedy, Brian O'Mahony, Sheila Roche et al. · European Journal Of Haematology · 2022 · 17 citations · Full text

Real‐world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow‐up in a national adult cohort

Mairead O’Donovan, Catherine Bergin, Eimear Quinn et al. · Haemophilia · 2021 · 16 citations · Full text

Physical activity, physical fitness and cardiometabolic risk amongst adults with moderate and severe haemophilia

Megan Kennedy, Sheila Roche, Mark McGowan et al. · Haemophilia · 2022 · 16 citations · Full text